950,000 Shares in enGene Holdings Inc. $ENGN Purchased by Eventide Asset Management LLC

Eventide Asset Management LLC acquired a new position in enGene Holdings Inc. (NASDAQ:ENGN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 950,000 shares of the company’s stock, valued at approximately $8,578,000. Eventide Asset Management LLC owned approximately 1.42% of enGene at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ENGN. Cresset Asset Management LLC purchased a new stake in enGene in the 2nd quarter worth about $36,000. Paloma Partners Management Co purchased a new stake in shares of enGene during the 2nd quarter worth about $38,000. Raymond James Financial Inc. raised its stake in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of enGene during the 3rd quarter worth about $76,000. Finally, PFS Partners LLC raised its stake in shares of enGene by 22.2% during the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after purchasing an additional 2,000 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Performance

Shares of NASDAQ ENGN opened at $1.62 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75. The firm has a market cap of $108.52 million, a price-to-earnings ratio of -0.72 and a beta of -0.29. The business’s 50-day simple moving average is $4.41 and its 200-day simple moving average is $7.24. enGene Holdings Inc. has a 52 week low of $1.40 and a 52 week high of $12.25.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ENGN. Weiss Ratings downgraded enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. Raymond James Financial downgraded enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price target for the company. in a research note on Friday, May 8th. UBS Group cut their price target on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Leerink Partners downgraded enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target for the company. in a research note on Friday, May 8th. Finally, Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.68.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.